XML 69 R17.htm IDEA: XBRL DOCUMENT
v3.23.3

COMMON SHARES | 12 Months Ended
--- | ---
Jun. 30, 2023
Equity [Abstract] |
COMMON SHARES |
| 11. | COMMON SHARES
| a) | Issuances
Fiscal Year 2023 Issuances In addition to the Common Shares issued in connection with the GXII Transaction, as discussed in Note 5, the following Common Share issuances occurred during fiscal year 2023: On April 28, 2023, the Company closed a registered direct offering and issued 314,465 Common Shares for $2.0 million, before deducting share issuance costs of $172. The Common Shares were sold pursuant to a securities purchase agreement, dated April 26, 2023, between the Company and a fund managed by Kingdon Capital Management, LLC. On June 9, 2023, the Company issued 100,000 Common Shares under the Yorkville Equity Facility Financing Agreement (discussed below) in exchange for $488 in cash proceeds. The Company recorded a non-cash operating expense of $13 which represented the difference between the proceeds received and the fair value of the Common Shares issued based on Nasdaq closing price per Common Share on the issuance date. Fiscal Year 2022 Issuances On June 30, 2022, the Company closed a non-brokered private placement (the “June 2022 Private Placement”) of units (the “Units”) of the Company. A total of 498,103 Units were issued at a price per Unit of C$0.96, for total gross proceeds to the Company of approximately C$4.8 million. Each Unit consists of one Common Share and one common share purchase warrant (“June 2022 Warrant”). Each June 2022 Warrant entitles the holder to acquire one Common Share at a price of C$1.10 at any time prior to July 1, 2024. Proceeds of the June 2022 Private Placement will be used for continued advancement of the Company’s Elk Creek Critical Minerals Project and for working capital and general corporate purposes. The Company paid cash commissions of C$62 and 6,510 warrants (the “Finder Warrants”), having the same terms as the June 2022 Warrants, to finders outside of the United States. The Finder Warrants were valued at C$18 using a risk-free rate of 3.2%, expected volatility of 64% and expected life of two years.
| b) | Stock Options
On November 5, 2020, the Company’s shareholders voted to approve an amendment and restatement of its long-term incentive plan (the “2017 Amended Long-Term Incentive Plan”) and the granting of incentive securities thereunder until November 5, 2023. Under the 2017 Amended Long-Term Incentive Plan, the Board may, in its discretion from time to time, grant Options and share units (in the form of restricted share units and performance share units) to directors, employees and certain other service providers (as defined in the 2017 Amended Long-Term Incentive Plan) of the Company and affiliated entities selected by the Board. Subject to adjustment as described in the 2017 Amended Long-Term Incentive Plan, the aggregate number of Common Shares that may be reserved for issuance to participants under the 2017 Amended Long-Term Incentive Plan, together with all other security-based compensation arrangements of the Company, may not exceed 10% of the issued and outstanding Common Shares from time to time, and the Common Shares reserved for issuance upon settlement of share units will not exceed 5% of the issued and outstanding Common Shares from time to time. The 2017 Amended Long-Term Incentive Plan limits the maximum number of Common Shares issued to insiders (as defined under TSX rules for this purpose) within any one-year period, or issuable to insiders at any time, in the aggregate, under all security-based compensation arrangements (including the 2017 Amended Long-Term Incentive Plan) to 10% of the then issued and outstanding Common Shares. The 2017 Amended Long-Term Incentive Plan also limits the aggregate number of Common Shares that may be reserved for issuance to any one participant under the 2017 Amended Long-Term Incentive Plan, together with all other security-based compensation arrangements of the Company, to 5% of the then issued and outstanding Common Shares (on a non-diluted basis). Subject to the adjustment provisions of the 2017 Amended Long-Term Incentive Plan, the aggregate number of Common Shares actually issued or transferred by the Company upon the exercise of Incentive Stock Options will be limited as described above. The Board has power over the granting, amendment, administration, or settlement of any award. Stock option transactions are summarized as follows: Schedule of stock option
|  | Number of Options |  |  | Weighted Average Exercise Price |
Balance, June 30, 2020 |  |  | 1,912,940 |  |  |  | C$6.20 |
Granted |  |  | 370,000 |  |  |  | C$7.80 |
Exercised |  |  | (295,229 | ) |  |  | C$6.10 |
Cancelled/expired |  |  | (391,212 | ) |  |  | C$6.40 |
Balance, June 30, 2021 |  |  | 1,596,499 |  |  |  | C$6.50 |
Granted |  |  | 447,500 |  |  |  | C$13.30 |
Exercised |  |  | (205,153 | ) |  |  | C$7.00 |
Cancelled/expired |  |  | (392,446 | ) |  |  | C$7.70 |
Balance, June 30, 2022 |  |  | 1,446,400 |  |  |  | C$8.27 |
Granted |  |  | 578,000 |  |  |  | $6.95 |
Exercised |  |  | (265,129 | ) |  |  | C$4.99 |
Cancelled/expired |  |  | (217,771 | ) |  |  | C$5.87 |
Balance, June 30, 2023 |  |  | 1,541,500 |  |  |  | C$9.64 |
The following table summarizes information about stock options outstanding at June 30, 2023:
Exercise Price | Expiry Date | Number Outstanding | Aggregate Intrinsic Value | Number Exercisable | Aggregate Intrinsic Value
C$8.40 | September 18, 2023 | 105,000 | C$- | 105,000 | C$-
C$5.40 | November 15, 2023 | 208,500 | 263 | 208,500 | 263
C$7.50 | December 14, 2023 | 170,000 | - | 170,000 | -
C$7.50 | December 16, 2023 | 52,500 | - | 52,500 | -
C$13.60 | December 17, 2024 | 377,500 | - | 377,500 | -
C$11.00 | May 30, 2025 | 50,000 | - | 50,000 | -
$6.95 | March 27, 2026 | 578,000 | - | 578,000 | -
Balance, June 30, 2023 | 1,541,500 | C$263 | 1,541,500 | C$263
The aggregate intrinsic value in the preceding table represents the total intrinsic value, based on the Company’s closing stock price of C$6.68 as of June 30, 2023, which would have been received by the option holders had all option holders exercised their options as of that date. The total number of in-the-money options vested and exercisable as of June 30, 2023, was 208,500. The total intrinsic value of options exercised during the year ended June 30, 2023, was C$1,592. As of June 30, 2023, there were no unrecognized compensation costs related to unvested share-based compensation arrangements granted. The following table summarizes the weighted average information and assumptions used to determine option costs:
| Year ended June 30,
| 2023 | 2022 | 2021
Fair value per option granted during the period | $3.09 | C$4.90 | C$2.50
Risk-free interest rate | 3.30% | 1.33% | 0.26%
Expected dividend yield | 0% | 0% | 0%
Expected stock price volatility (historical basis) | 63.6% | 54.4% | 54.1%
Expected option life in years | 3.0 | 3.0 | 3.0
| c) | Warrants
Warrant transactions are summarized as follows. Weighted average exercise prices related to Canadian dollar denominated warrants were converted to U.S. dollars using end of period foreign currency exchange rates.
|  | Warrants |  |  | Weighted Average Exercise Price |
Balance, June 30, 2020 |  |  | 1,237,645 |  |  | $ | 5.43 |
Granted: |  |  |  |  |  |  |  |
Nordmin warrants |  |  | 50,000 |  |  |  | 6.45 |
Lind III warrants |  |  | 855,800 |  |  |  | 7.83 |
April 2021 private placement |  |  | 441,211 |  |  |  | 13.15 |
Exercised |  |  | (910,628 | ) |  |  | 6.05 |
Expired |  |  | (239,845 | ) |  |  | 5.89 |
Balance, June 30, 2021 |  |  | 1,434,183 |  |  |  | 9.36 |
Granted: |  |  |  |  |  |  |  |
June 2022 private placement |  |  | 504,614 |  |  |  | 8.54 |
Exercised |  |  | (87,175 | ) |  |  | 6.05 |
Balance, June 30, 2022 |  |  | 1,851,622 |  |  |  | 8.99 |
Granted: |  |  |  |  |  |  |  |
Yorkville financing warrants |  |  | 1,789,267 |  |  |  | 8.94 |
GXII warrants |  |  | 15,666,626 |  |  |  | 11.50 |
Expired |  |  | (491,211 | ) |  |  | 11.67 |
Balance, June 30, 2023 |  |  | 18,816,304 |  |  | $ | 10.98 |
At June 30, 2023, the Company has outstanding exercisable warrants, as follows:
Number |  | Exercise Price |  | Expiry Date
504,611 |  | C$11.00 |  | June 30, 2024
855,800 |  | C$9.70 |  | February 19, 2025
1,789,267 |  | $8.94 |  | (1)
15,666,626 |  | $11.50 |  | March 17, 2028
18,816,304 |  |  |  |
(1) | Expires in 12 equal monthly tranches beginning October 17, 2023
In connection with the Closing, pursuant to the Business Combination Agreement, the Company assumed the GXII Warrant Agreement and each GXII Warrant thereunder that was issued and outstanding immediately prior to the Closing Date was converted into one NioCorp Assumed Warrant pursuant to the GXII Warrant Agreement, as amended by an Assignment, Assumption and Amendment Agreement, dated March 17, 2023, among the Company, GXII, Continental Stock Transfer & Trust Company, as the existing warrant agent, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A, together as the successor warrant agent (the “NioCorp Assumed Warrant Agreement”). In connection with the Closing, NioCorp issued (a) 9,999,959 public NioCorp Assumed Warrants (the “Public Warrants”) in respect of the GXII Warrants that were publicly traded prior to the Closing and (b) 5,666,667 NioCorp Assumed Warrants (the “Private Warrants”) to the Sponsor in respect of the GXII Warrants that it held prior to the Closing, which NioCorp Assumed Warrants were subsequently distributed by the Sponsor to its members in connection with the Closing. Each NioCorp Assumed Warrant entitles the holder to the right to purchase 1.11829212 Common Shares at an exercise price of $11.50 per 1.11829212 Common Shares (subject to adjustments for stock splits, stock dividends, reorganizations, recapitalizations and the like). No fractional shares will be issued upon exercise of any NioCorp Assumed Warrants, and fractional shares that would otherwise be due to the exercising holder will be rounded down to the nearest whole Common Share. In no event will the Company be required to net cash settle any NioCorp Assumed Warrant. Public Warrants The Company may elect to redeem the Public Warrants subject to certain conditions, in whole and not in part, at a price of $0.01 per Public Warrant if (i) 30 days’ prior written notice of redemption is provided to the holders, (ii) the last reported sale price of the Common Shares equals or exceeds approximately $16.10 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders and (iii) there is an effective registration statement covering the Common Shares issuable upon exercise of the Public Warrants, and a current prospectus relating thereto, available through the redemption date. Upon issuance of a redemption notice by the Company, the warrant holders will have until the redemption date to exercise for cash, or, at the Company’s election, on a cashless basis. The Public Warrants are not precluded from equity classification and are accounted for as such on the date of issuance, and each balance sheet date thereafter. Because the Transactions resulted in an excess of liabilities over assets acquired, no value was ascribed to the Public Warrants. Private Warrants The Private Warrants: (i) will be exercisable either for cash or on a cashless basis at the holder’s option and (ii) will not be redeemable by the Company, in either case as long as the Private Warrants are held by the Sponsor, its members or any of their permitted transferees (as prescribed in the NioCorp Assumed Warrant Agreement). In accordance with the NioCorp Assumed Warrant Agreement, any Private Warrants that are held by someone other than the Sponsor, its members or any their permitted transferees are treated as Public Warrants. The Company accounts for the Private Warrants assumed in the Transactions in accordance with the guidance contained in ASC 815-40. Such guidance provides that because the Private Warrants do not meet the criteria for equity treatment thereunder, each Private Warrant must be recorded as a liability. This liability is carried as a component of Warrant Liabilities on the consolidated balance sheet and is subject to re-measurement at each balance sheet date. With each such re-measurement, the warrant liability will be adjusted to its current fair value, with the change in fair value recognized in the consolidated statement of operations and comprehensive loss. The Company will reassess the classification at each balance sheet date. The Company classifies Private Warrants as Level 2 instruments under the fair value hierarchy and estimated the fair value using a Black Scholes model with the following assumptions:
Key Valuation Input |  | March 17, 2023 |  |  | June 30, 2023 |
Stock price on valuation date |  | $ | 7.00 |  |  | $ | 5.03 |
Strike price |  | $ | 11.50 |  |  | $ | 11.50 |
Implied volatility of Public Warrants |  |  | 19.5 | % |  |  | 33.5 | %
Risk free rate |  |  | 3.47 | % |  |  | 4.18 | %
Dividend yield |  |  | 0 | % |  |  | 0 | %
Expected warrant life in years |  |  | 5.0 |  |  |  | 4.73 |
The change in the Private Warrants liability is presented below:
|  | Amount |
Initial valuation, March 17, 2023 |  | $ | 2,987 |
Change in valuation |  |  | 292 |
Valuation at June 30, 2023 |  | $ | 3,279 |
| d) | Yorkville Equity Facility Financing
Concurrent with the closing of the GXII Transaction, the Yorkville Equity Facility Financing became effective. Pursuant to the Yorkville Equity Facility Financing Agreement, Yorkville committed to purchase up to $65,000 of Common Shares (the “Commitment Amount”), at NioCorp’s direction from time to time for a period commencing upon the Closing Date and ending on the earliest of (i) the first day of the month next following the 36-month anniversary of the Closing, (ii) the date on which Yorkville shall have made payment of the full Commitment Amount and (iii) the date that the Yorkville Equity Facility Financing Agreement otherwise terminates in accordance with its terms (the “Commitment Period”), subject to certain limitations and the satisfaction of the conditions in the Yorkville Equity Facility Financing Agreement. The Common Shares that may be sold pursuant to the Yorkville Equity Facility Financing Agreement would be purchased by Yorkville at a purchase price equal to 97% of the daily volume-weighted average price of the Common Shares on Nasdaq or such other principal U.S. market for the Common Shares if the Common Shares are ever listed or traded on the New York Stock Exchange or the NYSE American as reported by Bloomberg Financial Markets (or, if not available, a similar service provider of national recognized standing) during the applicable pricing period, which is a period during a single trading day or a period of three consecutive trading days, at the Company’s option and subject to certain restrictions, in each case, defined based on when an Advance Notice (as defined in the Yorkville Equity Facility Financing Agreement) is submitted, subject to certain limitations. Pursuant to the terms of the Yorkville Equity Facility Financing Agreement, NioCorp issued 81,213 of Common Shares (the “Commitment Shares”) valued at $650 to Yorkville as consideration for its irrevocable commitment to purchase Common Shares under the Yorkville Equity Facility Financing Agreement. On June 9, 2023, NioCorp issued and sold 100,000 Common Shares to Yorkville under the Yorkville Equity Facility Financing Agreement. Additionally, NioCorp is required to pay Yorkville an aggregate fee of $1,500 in cash (the “Cash Fee”), including $500 that NioCorp paid on the Closing Date and an additional $250 NioCorp was paid as of June 30, 2023. NioCorp will pay the remaining $750 balance in installments over a 12-month period following the Closing Date, provided that it will have the right to prepay without penalty all or part of the remaining installments of the Cash Fee at any time. In addition, legal and other costs of $496 were incurred in connection with the Yorkville Equity Facility Financing and were expensed on the effective date. The following amounts related to the Yorkville Equity Facility Financing Agreement were expensed as other operating costs: Schedule of expenses as other operating costs
|  | Amount |
Yorkville Cash Fee |  | $ | 1,500 |
Fair value of Commitment Shares issued |  |  | 650 |
Legal and other related costs |  |  | 496 |
Net costs expensed to other operating expense |  | $ | 2,646 |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI https://asc.fasb.org/topic&trid=2208762 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI https://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration